The U.S. Securities and Exchange Commission (SEC) has initiated a 21-day public comment period for the Injective staking ETF filing.
Regulatory steps in the crypto market are accelerating. The SEC has taken Canary’s Injective staking ETF application under review and opened a 21-day comment period for investors and institutions to provide feedback. The regulator has up to 90 days to make a final decision.
The proposed ETF aims to track the native token of the Injective blockchain and would be listed on the Cboe BZX exchange if approved. Canary emphasized in its filing that Injective’s market capitalization of over $1.4 billion makes it more resilient against price manipulation.
Interest in staking ETFs is growing rapidly. Last week, VanEck filed for an ETF based on Solana’s liquid staking token JitoSOL, while REX-Osprey integrated staking rewards into its own ETF product. These developments highlight the rising demand from institutional investors for staking-focused financial instruments.
The SEC’s stance on staking is also becoming clearer. In May, the agency stated that most proof-of-stake mechanisms do not fall under its jurisdiction and that certain liquid staking activities are not considered securities. These clarifications have paved the way for new applications, with the Injective ETF standing out as one of the most notable examples.
